PELUSI, SERENA
 Distribuzione geografica
Continente #
NA - Nord America 5.884
AS - Asia 5.163
EU - Europa 4.682
SA - Sud America 428
AF - Africa 144
OC - Oceania 51
Continente sconosciuto - Info sul continente non disponibili 7
Totale 16.359
Nazione #
US - Stati Uniti d'America 5.626
CN - Cina 1.889
IT - Italia 1.385
SG - Singapore 1.215
GB - Regno Unito 1.097
HK - Hong Kong 410
DE - Germania 385
BR - Brasile 345
VN - Vietnam 334
RU - Federazione Russa 286
SE - Svezia 269
BD - Bangladesh 242
IN - India 218
FR - Francia 206
NL - Olanda 185
FI - Finlandia 177
JP - Giappone 166
KR - Corea 143
CA - Canada 127
IE - Irlanda 127
ES - Italia 105
TR - Turchia 102
ID - Indonesia 99
MX - Messico 93
TW - Taiwan 91
BE - Belgio 67
DK - Danimarca 62
PL - Polonia 55
AU - Australia 47
CH - Svizzera 45
EG - Egitto 43
CI - Costa d'Avorio 38
IR - Iran 38
GR - Grecia 31
RS - Serbia 30
AT - Austria 28
PK - Pakistan 27
PT - Portogallo 27
TH - Thailandia 24
AR - Argentina 22
IQ - Iraq 22
UA - Ucraina 20
SA - Arabia Saudita 19
CO - Colombia 17
ZA - Sudafrica 17
MY - Malesia 15
IL - Israele 13
BG - Bulgaria 12
RO - Romania 12
CZ - Repubblica Ceca 11
HU - Ungheria 11
NO - Norvegia 11
UZ - Uzbekistan 10
CL - Cile 9
EC - Ecuador 9
PH - Filippine 9
LT - Lituania 8
NP - Nepal 8
AE - Emirati Arabi Uniti 7
DO - Repubblica Dominicana 7
DZ - Algeria 7
JO - Giordania 7
LU - Lussemburgo 7
MA - Marocco 7
MN - Mongolia 7
PR - Porto Rico 7
VE - Venezuela 7
CR - Costa Rica 6
JM - Giamaica 6
KH - Cambogia 6
BO - Bolivia 5
CY - Cipro 5
EE - Estonia 5
KE - Kenya 5
MD - Moldavia 5
MM - Myanmar 5
MO - Macao, regione amministrativa speciale della Cina 5
PY - Paraguay 5
TN - Tunisia 5
UY - Uruguay 5
EU - Europa 4
HN - Honduras 4
LK - Sri Lanka 4
NZ - Nuova Zelanda 4
OM - Oman 4
SI - Slovenia 4
AL - Albania 3
AO - Angola 3
AZ - Azerbaigian 3
CM - Camerun 3
GT - Guatemala 3
PE - Perù 3
PS - Palestinian Territory 3
SD - Sudan 3
TZ - Tanzania 3
AP - ???statistics.table.value.countryCode.AP??? 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
KG - Kirghizistan 2
LV - Lettonia 2
Totale 16.331
Città #
Houston 1.448
Southend 887
Singapore 790
Ashburn 475
Hong Kong 320
Milan 310
Dallas 280
San Jose 256
Beijing 237
Fairfield 231
Chandler 199
Council Bluffs 162
Wilmington 145
Ann Arbor 138
New York 132
Helsinki 125
Seattle 121
Dublin 118
Los Angeles 109
Shanghai 106
Frankfurt am Main 95
Guangzhou 93
Ho Chi Minh City 92
Woodbridge 88
Cambridge 86
Santa Clara 82
Jakarta 81
Nanjing 81
Hanoi 80
Princeton 76
Munich 74
Hefei 70
Tokyo 66
Dearborn 61
Redwood City 58
Rome 56
São Paulo 56
Hangzhou 51
Lauterbourg 50
Moscow 49
Buffalo 47
Bengaluru 46
Toronto 44
The Dalles 43
Chengdu 42
Columbus 40
Abidjan 37
Phoenix 36
Nuremberg 35
Istanbul 34
Seoul 34
Chicago 33
Wuhan 32
Changsha 31
Ankara 30
Atlanta 30
Des Moines 30
Turin 30
Boardman 29
Taipei 29
Tianjin 29
Jinan 28
Berlin 27
London 27
Madrid 27
Naples 27
Brussels 25
Shenzhen 25
Taichung 24
Amsterdam 23
Shenyang 23
Brooklyn 22
Guadalajara 22
Boston 21
Paris 21
Piscataway 21
Verona 21
Warsaw 21
Ghent 20
Suzhou 19
Zurich 19
Bari 18
Haiphong 18
Pusan 18
Washington 18
Cairo 17
San Diego 17
Da Nang 16
Florence 16
Montreal 16
Ottawa 16
Rio de Janeiro 16
Vienna 16
Xi'an 16
Bangkok 15
Denver 15
Lappeenranta 15
Philadelphia 15
Cangzhou 14
Dong Ket 14
Totale 9.544
Nome #
Risk of obstructive sleep apnea with daytime sleepiness is associated with liver damage in non-morbidly obese patients with nonalcoholic Fatty liver disease 1.641
Mapping the human genetic architecture of COVID-19 1.116
Sexual dimorphism of metabolic dysfunction-associated steatotic liver disease 1.046
Genomewide Association Study of Severe Covid-19 with Respiratory Failure 620
Hepatic Fat-Genetic Risk Score Predicts Hepatocellular Carcinoma in Patients With Cirrhotic HCV Treated With DAAs 597
Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis 543
Hepcidin levels in chronic hemodialysis patients : A critical evaluation 509
HFE mutations and iron in hemodialysis patients 406
Detailed stratified GWAS analysis for severe COVID-19 in four European populations 402
IMPACT OF WHOLE EXOME SEQUENCING (WES) ON THE CLINICAL MANAGEMENT OF PATIENTS WITH ADVANCED NONALCOHOLIC FATTY LIVER (NAFL) 384
Causal relationship of hepatic fat with liver damage and insulin resistance in nonalcoholic fatty liver 377
Adverse effect of PNPLA3 p.I148M genetic variant on kidney function in middle-aged individuals with metabolic dysfunction 342
Renin-Angiotensin System Inhibitors, Type 2 Diabetes and Fibrosis Progression : An Observational Study in Patients with Nonalcoholic Fatty Liver Disease 328
Rare Pathogenic Variants Predispose to Hepatocellular Carcinoma in Nonalcoholic Fatty Liver Disease 318
Telomerase reverse transcriptase germline mutations and hepatocellular carcinoma in patients with nonalcoholic fatty liver disease 316
Liver transcriptomics highlights interleukin-32 as novel NAFLD-related cytokine and candidate biomarker 312
Impact of PNPLA3 rs738409 Polymorphism on the Development of Liver-Related Events in Patients with Nonalcoholic Fatty Liver Disease 300
PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients 297
PNPLA3 overexpression results in reduction of proteins predisposing to fibrosis 286
The A736V TMPRSS6 Polymorphism Influences Hepatic Iron Overload in Nonalcoholic Fatty Liver Disease 281
The A736V TMPRSS6 polymorphism influences hepcidin and iron metabolism in chronic hemodialysis patients : TMPRSS6 and hepcidin in hemodialysis 269
Interaction between estrogen receptor-α and PNPLA3 p.I148M variant drives fatty liver disease susceptibility in women 252
Genetic insight into Covid-19 related liver injury 245
Protein phosphatase 1 regulatory subunit 3B gene variation protects against hepatic fat accumulation and fibrosis in individuals at high risk of nonalcoholic fatty liver disease 244
Increased circulating adiponectin in males with chronic HCV hepatitis 237
Transmembrane 6 Superfamily Member 2 Gene Variant Disentangles Nonalcoholic Steatohepatitis From Cardiovascular Disease 228
Hepcidin and HFE protein: Iron metabolism as a target for the anemia of chronic kidney disease 227
Mboat7 down-regulation by hyper-insulinemia induces fat accumulation in hepatocytes: Mboat7 reduction and hepatic steatosis 227
Progressively invalidating orthostatic hypotension : a common symptom for a challenging diagnosis 224
SARS-CoV-2 seroprevalence trends in healthy blood donors during the COVID-19 outbreak in Milan 224
Impact of natural neuromedin-B receptor variants on iron metabolism 221
Dysmetabolism, Diabetes and Clinical Outcomes in Patients Cured of Chronic Hepatitis C: A Real-Life Cohort Study 214
Effect of the A736V TMPRSS6 polymorphism on the penetrance and clinical expression of hereditary hemochromatosis 213
Hepcidin resistance in dysmetabolic iron overload 212
Rare ATG7 genetic variants predispose patients to severe fatty liver disease 196
Definition of Healthy Ranges for Alanine Aminotransferase Levels: A 2021 Update 189
Redefining fatty liver disease classification in 2020 186
Progressive splenomegaly and mild thrombocytosis in beta-thalassaemia trait and coexisting hereditary hemochromatosis: possible confounders for a subsequent hematological diagnosis 181
Performance of non-invasive tests and histology for the prediction of clinical outcomes in patients with non-alcoholic fatty liver disease: an individual participant data meta-analysis 171
Circulating Interlukin-32 and Altered Blood Pressure Control in Individuals with Metabolic Dysfunction 165
Clinical and genetic determinants of the fatty liver–coagulation balance interplay in individuals with metabolic dysfunction 163
Juvenile hemochromatosis associated with heterozygosity for novel hemojuvelin mutations and with unknown cofactors 156
Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD 148
Extrapulmonary tuberculosis : an unusual presentation in an immunocompetent patient 141
Obesity Modifies the Performance of Fibrosis Biomarkers in Nonalcoholic Fatty Liver Disease 134
Non-invasive stratification of hepatocellular carcinoma risk in non-alcoholic fatty liver using polygenic risk scores 133
Trends and risk factors of SARS-CoV-2 infection in asymptomatic blood donors 122
Hepatic fat as clinical outcome and therapeutic target for nonalcoholic fatty liver disease 117
MetSCORE: a molecular metric to evaluate the risk of metabolic syndrome based on serum NMR metabolomics 116
An unbiased ranking of murine dietary models based on their proximity to human metabolic dysfunction-associated steatotic liver disease (MASLD) 116
Diagnostic Uptake of Targeted Sequencing in Adults With Steatotic Liver Disease and a Suspected Genetic Contribution 114
Validation of a targeted gene panel sequencing for the diagnosis of hereditary chronic liver diseases 107
Clinical exome sequencing for diagnosing severe cryptogenic liver disease in adults: A case series 105
Building mass to prevent non-alcoholic fatty liver disease? 93
Whole exome sequencing for personalized hepatology : expanding applications in adults and challenges 86
Reply to: “Polygenic risk score: A promising predictor for hepatocellular carcinoma in the population with non-alcoholic fatty liver disease” 68
Carriage of rare APOB variants predisposes to severe steatotic liver disease and hepatocellular carcinoma 53
Targeting the Liver Serine Protease TMPRSS6 Ameliorates Steatosis and Attenuates Fibrosis in Experimental MASLD 28
Rare Atg7 Genetic Variants Predispose to Severe Fatty Liver Disease 27
null 17
Interplay among lipoprotein(a), hepatic and vascular damage in individuals with metabolic dysfunction 5
null 3
null 1
Totale 16.799
Categoria #
all - tutte 39.834
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 39.834


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021245 0 0 0 0 0 0 0 0 0 0 122 123
2021/20221.168 99 86 101 124 80 104 82 78 120 66 103 125
2022/20231.170 96 120 98 90 150 158 61 76 143 24 82 72
2023/20241.286 77 111 77 131 246 81 104 67 79 67 115 131
2024/20252.846 110 265 99 252 194 194 224 251 201 237 307 512
2025/20265.577 497 364 600 365 468 456 715 415 590 408 699 0
Totale 16.799